{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:14:23Z","timestamp":1794327263112,"version":"4.9.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T00:00:00Z","timestamp":1649980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T00:00:00Z","timestamp":1649980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD06\/006"],"award-info":[{"award-number":["RD06\/006"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD12\/0017\/0018"],"award-info":[{"award-number":["RD12\/0017\/0018"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD16\/0002\/0006"],"award-info":[{"award-number":["RD16\/0002\/0006"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To study whether the association between the CD4\/CD8 ratio variation over time and the development of clinical outcomes vary in late presenters (CD4 count\u2009&lt;\u2009350\/\u00b5L or AIDS event at enrolment) or advanced presenters (CD4 count\u2009&lt;\u2009200\/\u00b5L or AIDS event at enrolment).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We included ART-na\u00efve adults from the Cohort of the Spanish HIV\/AIDS Research Network (CoRIS) enrolled between January 2004 up to November 2018 and with at least 6\u00a0months of follow-up. We used extended Cox proportional hazard models to estimate the hazard ratios (HRs) for the association between CD4\/CD8 ratio over time and a composite endpoint of the occurrence of the first AIDS event, first serious non-AIDS event or overall mortality occurring from 6\u00a0months after enrolment. HRs in non-late, late and advanced presenters were obtained by including an interaction term between late presentation status and CD4\/CD8 ratio over time.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 10,018 participants, 55.6% were late presenters and 26.5% were advanced presenters. Compared with CD4\/CD8 ratio\u2009&gt;\u20090.4, CD4\/CD8 ratio\u2009\u2264\u20090.4 over time was associated with an increased risk of experiencing the composite endpoint in non-late (HR 1.90; 95%CI 1.48, 2.43), late (HR 1.94; 1.46, 2.57) and advanced presenters (HR 1.72; 1.26, 2.34). Similarly, CD4\/CD8 ratio\u2009\u2264\u20090.4 over time was associated with a higher risk of developing an AIDS event (HR 3.31; 2.23, 4.93 in non-late; HR 2.75; 1.78, 4.27 in late and HR 2.25; 1.34, 3.76 in advanced presenters) or serious non-AIDS event (HR 1.39; 0.96, 2.02 in non-late, HR 1.62; 1.10, 2.40 in late and HR 1.49; 0.97, 2.29 in advanced presenters) as well as with a higher risk of overall mortality (HR 1.49; 0.92, 2.41 in non-late, HR 1.80; 1.04, 3.11 in late and HR 1.61; 0.92, 2.83 in advanced presenters) compared to CD4\/CD8\u2009&gt;\u20090.4, regardless of the late presentation status.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>A low CD4\/CD8 measured over time is associated with increased risk of morbidity and mortality in people living with HIV independently of their late presentation status. These data support the prognostic role of CD4\/CD8 over time and can help defining a subgroup of patients who need closer monitoring to avoid comorbidities.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-022-07352-z","type":"journal-article","created":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T14:03:19Z","timestamp":1650031399000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Low CD4\/CD8 ratio is associated with increased morbidity and mortality in late and non-late presenters: results from a multicentre cohort study, 2004\u20132018"],"prefix":"10.1186","volume":"22","author":[{"given":"Lourdes","family":"Dom\u00ednguez-Dom\u00ednguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2260-9370","authenticated-orcid":false,"given":"Marta","family":"Rava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otilia","family":"Bisbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Lopez-Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Portilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Podzamczer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juli\u00e1n","family":"Olalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Fuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Jarr\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio","family":"Iribarren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Cohort of the Spanish HIV\/AIDS Research Network (CoRIS)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,15]]},"reference":[{"issue":"8","key":"7352_CR1","doi-asserted-by":"publisher","first-page":"e349","DOI":"10.1016\/S2352-3018(17)30066-8","volume":"4","author":"A Trickey","year":"2017","unstructured":"Trickey A, May MT, Vehreschild JJ, Obel N, Gill MJ, Crane HM, et al. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017;4(8):e349\u201356.","journal-title":"Lancet HIV"},{"issue":"11","key":"7352_CR2","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/cid\/cir627","volume":"53","author":"G Guaraldi","year":"2011","unstructured":"Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53(11):1120\u20136.","journal-title":"Clin Infect Dis"},{"issue":"70","key":"7352_CR3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ijid.2018.02.009","volume":"2019","author":"RA Maciel","year":"2018","unstructured":"Maciel RA, Kl\u00fcck HM, Durand M, Sprinz E. Comorbidity is more common and occurs earlier in persons living with HIV than in HIV-uninfected matched controls, aged 50 years and older: a cross-sectional study. Int J Infect Dis. 2018;2019(70):30\u20135.","journal-title":"Int J Infect Dis"},{"key":"7352_CR4","doi-asserted-by":"crossref","unstructured":"Mocroft A, Lundgren JD, Sabin ML, d\u2019Arminio-Monforte A, Brockmeyer N, Casabona J, et al. Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med. 2013;10(9):e1001510.","DOI":"10.1371\/journal.pmed.1001510"},{"key":"7352_CR5","doi-asserted-by":"crossref","unstructured":"Rava M, Dom\u00ednguez-Dom\u00ednguez L, Bisbal O, L\u00f3pez-Cort\u00e9s LF, Busca C, Antela A, et al. Late presentation for HIV remains a major health issue in Spain: results from a multicenter cohort study, 2004\u20132018. Andrei G, editor. PLoS ONE. 2021;16(4):e0249864.","DOI":"10.1371\/journal.pone.0249864"},{"issue":"Suppl 2","key":"7352_CR6","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1093\/infdis\/jiw275","volume":"214","author":"PW Hunt","year":"2016","unstructured":"Hunt PW, Lee SA, Siedner MJ. Immunologic biomarkers, morbidity, and mortality in treated HIV infection. J Infect Dis. 2016;214(Suppl 2):S44-50.","journal-title":"J Infect Dis"},{"key":"7352_CR7","doi-asserted-by":"crossref","unstructured":"Lu W, Mehraj V, Vyboh K, Cao W, Li T, Routy JP. CD4:CD8 ratio as a frontier marker for clinical outcome, immune dysfunction and viral reservoir size in virologically suppressed HIV-positive patients. J Int AIDS Soc. 2015;18(1)20052.","DOI":"10.7448\/IAS.18.1.20052"},{"key":"7352_CR8","doi-asserted-by":"crossref","unstructured":"Serrano-Villar S, Sainz T, Lee SA, Hunt PW, Sinclair E, Shacklett BL, et al. HIV-infected individuals with low CD4\/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ t cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog. 2014;10(5):e1004078.","DOI":"10.1371\/journal.ppat.1004078"},{"key":"7352_CR9","doi-asserted-by":"crossref","unstructured":"Serrano-Villar S, P\u00e9rez-El\u00edas MJ, Dronda F, Casado JL, Moreno A, Royuela A, et al. Increased risk of serious non-AIDS-related events in HIV-infected subjects on antiretroviral therapy associated with a low CD4\/CD8 ratio. PLoS ONE. 2014;9(1):e85798.","DOI":"10.1371\/journal.pone.0085798"},{"key":"7352_CR10","doi-asserted-by":"crossref","unstructured":"The Strategies for Management of Antiretorviral Therapy (SMART) Study Group. Major clinical outcomes in antiretroviral therapy (ART)\u2013naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis. 2008;197:1133\u201344.","DOI":"10.1086\/586713"},{"issue":"1","key":"7352_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1157\/13096749","volume":"25","author":"AM Caro-Murillo","year":"2007","unstructured":"Caro-Murillo AM, Castilla J, P\u00e9rez-Hoyos S, Mir\u00f3 JM, Podzamczer D, Rubio R, et al. Spanish cohort of na\u00efve HIV-infected patients (CoRIS): rationale, organization and initial results. Enferm Infecc Microbiol Clin. 2007;25(1):23\u201331.","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"1","key":"7352_CR12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1468-1293.2010.00857.x","volume":"12","author":"A Antinori","year":"2011","unstructured":"Antinori A, Coenen T, Costagiola D, Dedes N, Ellefson M, Gatell J, et al. Late presentation of HIV infection: a consensus definition. HIV Med. 2011;12(1):61\u20134.","journal-title":"HIV Med"},{"key":"7352_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modeling survival data: extending the Cox model (statistics for biology and health)","author":"TM Therneau","year":"2000","unstructured":"Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model (statistics for biology and health). New York: Springer; 2000."},{"key":"7352_CR14","unstructured":"R Development Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna; 2019."},{"key":"7352_CR15","unstructured":"Therneau TM. A package for survival analysis in R. R package version 3.2-13. 2021."},{"issue":"3","key":"7352_CR16","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1016\/S2352-3018(15)00006-5","volume":"2","author":"C Mussini","year":"2015","unstructured":"Mussini C, Lorenzini P, Cozzi-Lepri A, Lapadula G, Marchetti G, Nicastri E, et al. CD4\/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. Lancet HIV. 2015;2(3):e98-106.","journal-title":"Lancet HIV"},{"issue":"1","key":"7352_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12981-018-0200-4","volume":"15","author":"WM Han","year":"2018","unstructured":"Han WM, Apornpong T, Kerr SJ, Hiransuthikul A, Gatechompol S, Do T, et al. CD4\/CD8 ratio normalization rates and low ratio as prognostic marker for non-AIDS defining events among long-term virologically suppressed people living with HIV. AIDS Res Ther. 2018;15(1):13.","journal-title":"AIDS Res Ther"},{"key":"7352_CR18","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2020.0106","author":"H Okhai","year":"2020","unstructured":"Okhai H, Vivancos-Gallego MJ, Hill T, Sabin CA. CD4+:CD8+ T cell ratio normalization and the development of AIDS events in people with HIV starting antiretroviral therapy. AIDS Res Hum Retrovir. 2020. https:\/\/doi.org\/10.1089\/aid.2020.0106.","journal-title":"AIDS Res Hum Retrovir"},{"issue":"6","key":"7352_CR19","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1093\/cid\/ciy176","volume":"67","author":"Y Mutoh","year":"2018","unstructured":"Mutoh Y, Nishijima T, Inaba Y, Tanaka N, Kikuchi Y, Gatanaga H, et al. Incomplete recovery of CD4 cell count, CD4 percentage, and CD4\/CD8 ratio in patients with human immunodeficiency virus infection and suppressed viremia during long-term antiretroviral therapy. Clin Infect Dis. 2018;67(6):927\u201333.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"7352_CR20","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1097\/QAD.0000000000001005","volume":"30","author":"JL Castilho","year":"2016","unstructured":"Castilho JL, Shepherd BE, Koethe J, Turner M, Bebawy S, Logan J, et al. CD4+\/CD8+ ratio, age, and risk of serious noncommunicable diseases in HIV-infected adults on antiretroviral therapy. AIDS. 2016;30(6):899\u2013908.","journal-title":"AIDS"},{"key":"7352_CR21","doi-asserted-by":"crossref","unstructured":"Hema MN, Ferry T, Dupon M, Cuzin L, Verdon R, Thi\u00e9baut R, et al. Low CD4\/CD8 ratio is associated with non AIDS-defining cancers in patients on antiretroviral therapy: ANRS CO8 (Aproco\/Copilote) prospective cohort study. Apetrei C, editor. PLoS ONE. 2016;11(8):e0161594.","DOI":"10.1371\/journal.pone.0161594"},{"issue":"25","key":"7352_CR22","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1016\/j.jacc.2017.05.012","volume":"69","author":"A Kearns","year":"2017","unstructured":"Kearns A, Gordon J, Burdo TH, Qin X. HIV-1-associated atherosclerosis: unraveling the missing link. J Am Coll Cardiol. 2017;69(25):3084\u201398.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"7352_CR23","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/apm.13020","volume":"128","author":"MM Silva Neto","year":"2020","unstructured":"Silva Neto MM, Brites C, Borges \u00c1H. Cancer during HIV infection. APMIS. 2020;128(2):121\u20138.","journal-title":"APMIS"},{"key":"7352_CR24","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/hiv.12081","volume":"15","author":"S Serrano-Villar","year":"2014","unstructured":"Serrano-Villar S, Moreno S, Fuentes-Ferrer M, S\u00e1nchez-Marcos C, \u00c1vila M, Sainz T, et al. The CD4:CD8 ratio is associated with markers of age-associated disease in virally suppressed HIV-infected patients with immunological recovery. HIV Med. 2014;15:40\u20139.","journal-title":"HIV Med"},{"issue":"7","key":"7352_CR25","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1089\/aid.2015.0385","volume":"32","author":"E Bernal-Morell","year":"2016","unstructured":"Bernal-Morell E, Serrano-Cabeza J, Mu\u00f1oz \u00c1, Mar\u00edn I, Masi\u00e1 M, Guti\u00e9rrez F, et al. The CD4\/CD8 ratio is inversely associated with cIMT progression in HIV infected patients on antiretroviral treatment. AIDS Res Hum Retrovir. 2016;32(7):648\u201353.","journal-title":"AIDS Res Hum Retrovir"},{"key":"7352_CR26","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/bjc.2011.558","volume":"106","author":"GM Clifford","year":"2012","unstructured":"Clifford GM, Lise M, Franceschi S, Egger M, Bouchardy C, Korol D, et al. Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection. Br J Cancer. 2012;106:447\u201352.","journal-title":"Br J Cancer"},{"issue":"2","key":"7352_CR27","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1016\/S2352-3018(16)30215-6","volume":"4","author":"K Sigel","year":"2017","unstructured":"Sigel K, Wisnivesky J, Crothers K, Gordon K, Brown ST, Rimland D, et al. Immunological and infectious risk factors for lung cancer in US veterans with HIV: a longitudinal cohort study. Lancet HIV. 2017;4(2):e67-73.","journal-title":"Lancet HIV"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07352-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-022-07352-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07352-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T15:03:11Z","timestamp":1650121391000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07352-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,15]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7352"],"URL":"https:\/\/doi.org\/10.1186\/s12879-022-07352-z","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,15]]},"assertion":[{"value":"6 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The CoRIS cohort was approved by the Research Ethic Committee of the Gregorio Mara\u00f1\u00f3n Hospital and the study was approved by the Research Ethic Committee of the \u201c12 de Octubre\u201d Hospital (Number 14\/080). All the patients signed informed consent to participate in the CoRIS cohort.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MR has received a grant from Gilead Science. IJ has received teaching fees from Viiv and advisory fees from Gilead Science. SM has been involved in speaking activities and has received grants for research from Gilead, Janssen Cilag, Merck Sharp&Dohme, and ViiV Healthcare. RR reports personal fees from ViiV Healthcare and Merck Sharp & Dohme; grants and personal fees from Gilead Sciences and Janssen Cilag. OB reports payments for lectures by Gilead Sciences and ViiV Healthcare, and non-financial support for national conference and national HIV courses from ViiV Healthcare and Merck Sharp and Dohme, outside the submitted work. LD has received honoraria for lectures by Gilead Sciences and ViiV Healthcare, and non-financial support for HIV conferences and courses from Gilead, ViiV Healthcare and Merck Sharp and Dohme, outside the submitted work. All other authors declare that they have no conflict of interest related to this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"379"}}